{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T18:21:46Z","timestamp":1777486906878,"version":"3.51.4"},"reference-count":30,"publisher":"Wiley","issue":"15","license":[{"start":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:p>There is still much progress to be made in understanding the underlying mechanisms of brain metastasis development and its optimal therapy in non\u2013small cell lung cancer (NSCLC); it is very important to expand research in this area because brain metastasis strongly affects patients' quality of life and overall survival. This editorial reviews the available data in the context of a recent meta\u2010analysis of the pivotal IMpower130, IMpower131, and IMpower150 studies, which explores metastatic epidermal growth factor receptor and anaplastic lymphoma kinase wild\u2010type NSCLC to determine potential preventative factors and risk factors for the development of brain metastasis, specifically the question of whether immunotherapy (the anti\u2013programmed death ligand 1 antibody, atezolizumab in particular) plays a role in preventing brain metastasis.<\/jats:p>","DOI":"10.1002\/cncr.35350","type":"journal-article","created":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T14:28:50Z","timestamp":1715005730000},"page":"2577-2581","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immunotherapy for metastatic non\u2013small cell lung cancer: Is it really a no\u2010brainer?"],"prefix":"10.1002","volume":"130","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1460-5257","authenticated-orcid":false,"given":"Lauren K.","family":"Young","sequence":"first","affiliation":[{"name":"Department of Oncology Montefiore Medical Center Albert Einstein College of Medicine  Bronx New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7548-8360","authenticated-orcid":false,"given":"Balazs","family":"Halmos","sequence":"additional","affiliation":[{"name":"Department of Oncology Montefiore Medical Center Albert Einstein College of Medicine  Bronx New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,5,6]]},"reference":[{"key":"e_1_2_3_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.06.017"},{"key":"e_1_2_3_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030844"},{"key":"e_1_2_3_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.12.149"},{"key":"e_1_2_3_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306434"},{"key":"e_1_2_3_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35242"},{"key":"e_1_2_3_7_1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr\u201023\u2010245"},{"key":"e_1_2_3_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501824"},{"key":"e_1_2_3_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(15)01281\u20107"},{"key":"e_1_2_3_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2021.100205"},{"key":"e_1_2_3_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.10.014"},{"key":"e_1_2_3_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/1758835918769391"},{"key":"e_1_2_3_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(20)30111\u2010X"},{"key":"e_1_2_3_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02561"},{"key":"e_1_2_3_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010019\u201054513\u20103"},{"key":"e_1_2_3_16_1","doi-asserted-by":"publisher","DOI":"10.1515\/med-2020-0192"},{"key":"e_1_2_3_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(19)30167\u20106"},{"key":"e_1_2_3_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.03.028"},{"key":"e_1_2_3_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716948"},{"key":"e_1_2_3_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01818-7"},{"key":"e_1_2_3_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107322"},{"key":"e_1_2_3_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2022.2059874"},{"key":"e_1_2_3_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32517-X"},{"key":"e_1_2_3_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.12.017"},{"key":"e_1_2_3_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01308"},{"key":"e_1_2_3_26_1","volume-title":"Cemiplimab for the Treatment of Untreated Brain Metastases from PD\u2010L1 >= 50% Non\u2010Small Cell Lung Cancer"},{"key":"e_1_2_3_27_1","volume-title":"Pembrolizumab and Lenvatinib for the Treatment of Triple\u2010Negative Breast Cancer, Non\u2010Small Cell Lung Cancer, and Other Tumors With Brain Metastases"},{"key":"e_1_2_3_28_1","volume-title":"Tiragolumab with Carboplatin, Pemetrexed, and Atezolizumab for the Treatment of Non\u2010Squamous Non\u2010Small Cell Lung Cancer and Untreated Brain Metastases"},{"key":"e_1_2_3_29_1","volume-title":"Pembrolizumab and Bevacizumab in Treating Patients With Metastatic Melanoma or Non\u2010Small Cell Lung Cancer With Untreated Brain Metastases"},{"key":"e_1_2_3_30_1","volume-title":"Blood\u2010Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets"},{"key":"e_1_2_3_31_1","unstructured":"Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of\u00a0Stage IV or Recurrent Non\u2010Small Cell Lung Cancer Following Immunotherapy Pragmatica\u2010Lung Study.ClinicalTrials.gov. Accessed February 15 2024.https:\/\/clinicaltrials.gov\/study\/NCT05633602"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.35350","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T10:08:56Z","timestamp":1760263736000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.35350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,6]]},"references-count":30,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1002\/cncr.35350"],"URL":"https:\/\/doi.org\/10.1002\/cncr.35350","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,6]]},"assertion":[{"value":"2024-05-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}